Christoph S Nabzdyk

Summary

Affiliation: Tufts Medical Center
Country: USA

Publications

  1. pmc Differential susceptibility of human primary aortic and coronary artery vascular cells to RNA interference
    Christoph S Nabzdyk
    Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Biochem Biophys Res Commun 425:261-5. 2012
  2. pmc High throughput RNAi assay optimization using adherent cell cytometry
    Christoph S Nabzdyk
    Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Transl Med 9:48. 2011
  3. pmc Thrombospondin-2 gene silencing in human aortic smooth muscle cells improves cell attachment
    Shunsuke Yoshida
    Department of Surgery, Division of Vascular Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Am Coll Surg 213:668-76. 2011
  4. pmc RNA interference-mediated survivin gene knockdown induces growth arrest and reduced migration of vascular smooth muscle cells
    Christoph S Nabzdyk
    Division of Vascular and Endovascular Surgery, Laboratory for Accelerated Vascular Research, University of California, San Francisco, CA 94143, USA
    Am J Physiol Heart Circ Physiol 301:H1841-9. 2011
  5. pmc The current national criteria for carotid artery stenting overestimate its efficacy in patients who are symptomatic and at high risk
    Shunsuke Yoshida
    Department of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    J Vasc Surg 58:120-7. 2013

Collaborators

Detail Information

Publications5

  1. pmc Differential susceptibility of human primary aortic and coronary artery vascular cells to RNA interference
    Christoph S Nabzdyk
    Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Biochem Biophys Res Commun 425:261-5. 2012
    ..The goal of this study was to investigate the intrinsic RNAi susceptibility of primary human aortic and coronary artery endothelial and vascular smooth muscle cells (AoEC, CoEC, AoSMC and CoSMC) using adherent cell cytometry...
  2. pmc High throughput RNAi assay optimization using adherent cell cytometry
    Christoph S Nabzdyk
    Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Transl Med 9:48. 2011
    ..In this study adherent cell cytometry was used to rapidly optimize siRNA transfection in human aortic vascular smooth muscle cells (AoSMC)...
  3. pmc Thrombospondin-2 gene silencing in human aortic smooth muscle cells improves cell attachment
    Shunsuke Yoshida
    Department of Surgery, Division of Vascular Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Am Coll Surg 213:668-76. 2011
    ..In this study, we hypothesized that inhibition of TSP-2 in human aortic smooth muscle cells (HAoSMCs) would reduce cell proliferation and migration in vitro, providing a therapeutic target to mitigate intimal hyperplasia...
  4. pmc RNA interference-mediated survivin gene knockdown induces growth arrest and reduced migration of vascular smooth muscle cells
    Christoph S Nabzdyk
    Division of Vascular and Endovascular Surgery, Laboratory for Accelerated Vascular Research, University of California, San Francisco, CA 94143, USA
    Am J Physiol Heart Circ Physiol 301:H1841-9. 2011
    ..Thus, treatment of VSMC with RNAi targeting SVV might limit the response to vascular injury without destabilizing the vessel wall...
  5. pmc The current national criteria for carotid artery stenting overestimate its efficacy in patients who are symptomatic and at high risk
    Shunsuke Yoshida
    Department of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    J Vasc Surg 58:120-7. 2013
    ..The validity of these high-risk criteria are yet unproven. In this study, we stratified patients who underwent CAS or CEA by CMS high-risk criteria and symptom status and examined their 30-day outcomes...